New York Life Investment Management LLC Boosts Holdings in United Therapeutics Co. (NASDAQ:UTHR)

New York Life Investment Management LLC grew its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 5,644 shares of the biotechnology company’s stock after buying an additional 238 shares during the period. New York Life Investment Management LLC’s holdings in United Therapeutics were worth $1,241,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. Cambridge Investment Research Advisors Inc. boosted its position in United Therapeutics by 9.0% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 1,705 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 141 shares during the period. Raymond James & Associates boosted its position in United Therapeutics by 1.7% during the third quarter. Raymond James & Associates now owns 28,054 shares of the biotechnology company’s stock worth $6,337,000 after purchasing an additional 471 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in United Therapeutics by 48.8% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 2,345 shares of the biotechnology company’s stock worth $530,000 after purchasing an additional 769 shares during the period. Advisor Partners II LLC boosted its position in United Therapeutics by 7.7% during the third quarter. Advisor Partners II LLC now owns 1,339 shares of the biotechnology company’s stock worth $302,000 after purchasing an additional 96 shares during the period. Finally, Park Avenue Securities LLC bought a new position in United Therapeutics during the third quarter worth about $303,000. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. SVB Leerink assumed coverage on shares of United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. The Goldman Sachs Group raised their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. Finally, Wells Fargo & Company raised their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $308.78.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $215.31, for a total value of $1,291,860.00. Following the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $7,880,130.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $7,880,130.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christopher Patusky sold 1,680 shares of United Therapeutics stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $224.00, for a total transaction of $376,320.00. Following the transaction, the director now directly owns 4 shares in the company, valued at $896. The disclosure for this sale can be found here. Insiders have sold 147,630 shares of company stock valued at $35,089,803 over the last three months. 12.50% of the stock is owned by corporate insiders.

United Therapeutics Trading Up 2.2 %

Shares of UTHR opened at $266.22 on Wednesday. The firm’s 50 day simple moving average is $238.38 and its 200 day simple moving average is $229.88. The company has a market capitalization of $11.81 billion, a P/E ratio of 12.59 and a beta of 0.54. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. United Therapeutics Co. has a 1-year low of $204.44 and a 1-year high of $266.65.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. United Therapeutics’s quarterly revenue was up 33.7% on a year-over-year basis. During the same period last year, the firm posted $4.86 earnings per share. Sell-side analysts forecast that United Therapeutics Co. will post 23.88 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.